Matthew M. Seavey

Cancer Immunotherapy Targeting the High Molecular Weight Melanoma-Associated Antigen Protein Results in a Broad Antitumor Response and Reduction of Pericytes in the Tumor Vasculature

Paulo Maciag, Matthew M. Seavey, Zhen-Kun Pan et al. · Cancer Research · 2008 · 91 citations · Full text

Life Sciences, Immunology, Oncology +17

Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human

Vafa Shahabi, Matthew M. Seavey, Paulo Maciag et al. · Cancer Gene Therapy · 2010 · 81 citations

Medicine, Immunology, Oncology +14

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis

Kristine L. Stump, Lily Lu, Paweł Dobrzański et al. · Arthritis Research & Therapy · 2011 · 76 citations · Full text

Medicine, Immunology, Pharmacology +17

Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2

Lily Lu, Kristine L. Stump, Nate H. Wallace et al. · The Journal of Immunology · 2011 · 75 citations · Full text

Medicine, Immunology, Pharmacology +16

An Anti-Vascular Endothelial Growth Factor Receptor 2/Fetal Liver Kinase-1 <i>Listeria monocytogenes</i> Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu+ Breast Tumors in a Mouse Model

Matthew M. Seavey, Paulo Maciag, Nada Al-Rawi et al. · The Journal of Immunology · 2009 · 71 citations · Full text

Medicine, Immunology, Oncology +17